(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 15.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Harmony Biosciences Holdings's revenue in 2025 is $744,852,000.On average, 4 Wall Street analysts forecast HRMY's revenue for 2025 to be $48,329,225,660, with the lowest HRMY revenue forecast at $47,437,827,956, and the highest HRMY revenue forecast at $49,159,409,039. On average, 3 Wall Street analysts forecast HRMY's revenue for 2026 to be $57,804,410,567, with the lowest HRMY revenue forecast at $54,277,466,319, and the highest HRMY revenue forecast at $60,186,428,744.
In 2027, HRMY is forecast to generate $66,387,049,285 in revenue, with the lowest revenue forecast at $59,353,776,118 and the highest revenue forecast at $71,648,322,816.